US · Healthcare · Biotechnology
EPS came in at -0.18 against a street estimate of -0.23 — a beat of 21.7%.
Analysts rate C4 Therapeutics Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $12.86.
| Fund | Stake |
|---|---|
| Morgan Stanley - Brokerage Accounts | 7.21% |
| RA Capital Management, LLC | 6.50% |
| BlackRock Inc | 6.42% |
| Lynx1 Capital Management, LP | 5.96% |
| Squadron Capital Management LLC | 5.85% |
| Bain Capital Life Sciences Investors, LLC | 5.83% |
| JPMorgan Chase & Co | 3.86% |
| Vanguard Capital Management, LLC | 3.59% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for C4 Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.